[1,7]naphthyridines as PDE4 inhibitors

Details [1,7]naphthyridines as PDE4 inhibitors [1,7]naphthyridines as PDE4 inhibitors

2003-12-15

2008-12-23

Seaman, D. Margaet (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S300000, C546S122000, C544S362000

Reexamination Certificate

active

07468370

ABSTRACT:
Compounds of formula Iin free or salt form, wherein R1, R2and R3have the meanings as indicated in the specification, are useful for treating conditions mediated by of phosphodiesterase type 4 or the down-regulation or inhibition of TNF-α release, particularly obstructive or inflammatory airways diseases. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

REFERENCES:
patent: 0 005 232 (1979-11-01), None
patent: 98/18796 (1998-05-01), None
A. Nakata et al., Clinical and Experimental Immunology, 2002, vol. 128, pp. 460-466.
Hersperger et al., “PD-Catalysed Cross-Coupling Reactions for the Synthesis of 6,8-Disubstituted 1.7-Naphtyridines: A Novel Class of Potent and Selective Phosphodiesterase Type 4D Inhibitors”, J. Med. Chem., vol. 43, pp. 675-682 (2000).

Affiliated with

Also associated with

Rating

[1,7]naphthyridines as PDE4 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with [1,7]naphthyridines as PDE4 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and [1,7]naphthyridines as PDE4 inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4029017